Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

$PAHC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PAHC alert in real time by email
0001069899false00010698992024-11-052024-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 6, 2024 (November 5, 2024)

Phibro Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

Delaware

    

001-36410

    

13-1840497

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

Glenpointe Centre East, 3rd Floor

300 Frank W. Burr Boulevard, Suite 21

Teaneck, New Jersey 07666-6712

(Address of Principal Executive Offices, including Zip Code)

(201) 329-7300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share

PAHC

NASDAQ Stock Market

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 2.02     RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 6, 2024, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2024 and its financial guidance for the fiscal year ending June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

On November 5, 2024, the Corporation held its annual meeting of stockholders (the “Meeting”). Present at the Meeting in person or by proxy were holders of 16,551,734 shares of Class A common stock of the Corporation and 20,166,034 shares of Class B common stock of the Corporation, which together represent 98.3% of the voting power of all shares of common stock of the Corporation as of September 13, 2024, the record date for the Meeting, and constituting a quorum for the transaction of business at the Meeting.

The stockholders of the Corporation voted on the following items at the Meeting:

1.To elect two Class II Directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified; and
2.to ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2025.

For more information about the foregoing proposals, see the Corporation’s 2024 Proxy Statement.

Holders of the shares of Class A common stock are entitled to one vote per share and holders of the shares of Class B common stock are entitled to ten votes per share. Holders of the shares of Class A common stock and holders of the shares of Class B common stock voted together as a single class on all matters (including the election of directors) submitted to a vote of stockholders at the Meeting.

The voting results for each of these proposals are detailed below.

1.Election of Class II Directors

vOTES

Director Nominee

Votes For

Votes Withheld

Broker Non-Votes

Mary Lou Malanoski

206,919,485

10,768,751

523,838

Carol A Wrenn

210,284,154

7,418,482

509,438

2.Ratification of the Selection of PwC as Independent Registered Public Accounting Firm

vOTES

Votes For

Votes Against

Abstained

217,280,346

929,806

1,920

There were no broker non-votes on this proposal.

Based on the votes set forth above, the stockholders ratified the selection of PwC as the Corporation’s independent registered public accounting firm for the fiscal year ending June 30, 2025.

ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit
Number

    

Description

99.1

 

Press Release, dated November 6, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHIBRO ANIMAL HEALTH CORPORATION

Registrant

Date: November 6, 2024

By: 

/s/ Judith Weinstein

Name:

Judith Weinstein

Title:

Senior Vice President, General Counsel and Corporate Secretary

Get the next $PAHC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PAHC

DatePrice TargetRatingAnalyst
9/10/2024$22.00Neutral
JP Morgan
12/7/2023$9.00Underperform
Exane BNP Paribas
12/21/2022$18.00Buy
ROTH Capital
7/25/2022$22.00Equal Weight → Underweight
Barclays
1/10/2022$23.00Underweight → Equal-Weight
Barclays
11/18/2021$23.00Equal-Weight
Morgan Stanley
8/5/2021$25.00Neutral
Credit Suisse
7/7/2021$23.00Equal-Weight → Underweight
Barclays
More analyst ratings

$PAHC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Phibro Animal Health Corporation to Participate at Barclays Annual Global Healthcare Conference

    Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Barclays Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Thursday, March 13, 2025, at 9:00 AM ET at the Loews Miami Beach Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted p

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phibro Animal Health Corporation to Participate at Bank of America 2025 Virtual Animal Health Summit

    Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Bank of America 2025 Virtual Animal Health Summit. Chief Financial Officer, Glenn David will address financial analysts and investors on Thursday, February 27, 2025, at 10:50 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PAHC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PAHC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PAHC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PAHC
SEC Filings

See more

$PAHC
Leadership Updates

Live Leadership Updates

See more
  • Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PAHC
Financials

Live finance-specific insights

See more
  • Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit w

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To

    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PAHC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more